Inrebic (Fedratinib Dihydrochloride) Patent Expiration, LOE Window & CMS Spending

Inrebic (Fedratinib Dihydrochloride) by Bristol Myers Squibb: FDA Orange Book core substance LOE 2031-11-16 (last listed 2039-09-24), 0 AB generics, $47.7M 2024 CMS Part D & Medicaid spend, and 3 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorBristol Myers Squibb
FDA Application & PathwayN212327 (NDA)
Exclusivity / Cliff HorizonLong-Dated Protection (2036+)
Core Active-Ingredient LOE Date2031-11-16
Last Listed Patent or Exclusivity Date2039-09-24
Orange Book Patents (*PED Extensions)5 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$47.7M
2024 Medicare Part D Spend$44.9M
2024 Medicaid Spend$2.7M
Reported Wholesale Price Change (CA SB 17)3 WAC filings (max 20.4% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Bristol Myers Squibb across sibling Meru public-data platforms.